Likewise, the response rate of immunotherapy in patients with PD-L1-overexpressed NSCLC ranged from 67% to 100%, compared to a significantly lower response rate of 0–15% in PD-L1-negative NSCLC [35]. Here, CD274 is linked to non-small cell lung carcinoma.